Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) and keeping the price target at $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc.’s aleniglipron in the competitive landscape of oral GLP-1 drugs. The decision by Pfizer to withdraw danuglipron due to liver toxicity and the promising results from Lilly’s orforglipron trial have set a benchmark for aleniglipron. Aleniglipron’s unique structural properties and its clear safety profile provide it with a competitive edge, suggesting it could achieve significant weight loss results in upcoming trials.
Furthermore, the pharmacokinetics of aleniglipron, which allow for rapid exposure and a manageable side effect profile, support its potential for achieving target weight loss. The drug’s differentiated effects, spanning from metabolic disorders to Type 2 diabetes, enhance its market penetration prospects. These factors, combined with the challenges faced by new entrants in penetrating established markets, underpin Ghosh’s optimistic outlook for the stock.
In another report released on April 15, JMP Securities also reiterated a Buy rating on the stock with a $87.00 price target.